Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Obesity-driven Endometrial Cancer
NCT03694834Phase 1Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Mar 2019
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in endometrial cancer (EC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Change in the number of Tumor Infiltrating Lymphocytes at 3 weeks. Started Mar 2019; status: terminated.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03694834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694834.